How Long Does Alectinib — Take to Work?

Not feeling a change in the early weeks is normal and does not mean the drug is not working. Alectinib acts at a molecular level inside cancer cells, and that process takes time before it translates into a symptom you can notice. Most objective responses — where a scan shows the tumour has shrunk — take eight to twelve weeks to become measurable by standard criteria. Your oncologist will not interpret the early weeks as success or failure. The first scan result is the first real data point, and the absence of early symptom change is not a bad sign.

Some patients notice that their overall sense of wellbeing fluctuates in the first few weeks, and this is not necessarily a sign that the cancer is progressing. Side effects from alectinib — such as muscle aches, leg swelling, or fatigue — may emerge and temporarily affect how you feel, independent of what the cancer is doing. If a symptom is clearly worsening — new breathlessness, new or worsening pain, or anything that feels different from before — report it to your team rather than waiting for the next scheduled appointment. A new or changing symptom needs assessment regardless of timing.

The first CT scan compares the current size of your tumour and any involved lymph nodes against the baseline measurements taken before you started alectinib. Your oncologist uses standard measurement criteria — called RECIST — to classify the result as a response, stable disease, or progression. The scan result, alongside how you are feeling and your blood test results, shapes what happens next. One scan is a milestone, not a final verdict — subsequent scans track the pattern over time and give your team a clearer picture of how the cancer is behaving.

No. Stable disease means the cancer has not grown, which is a meaningful and intended outcome for a treatment designed to control the disease over an extended period. For many patients with ALK-positive lung cancer, stable disease on alectinib is a sustained state that continues across multiple scan cycles. Your oncologist will track the pattern and will explain when a change in approach is needed. A single scan showing stable disease, in the early months of treatment, is not a failure signal and should not be read as one.

Your team monitors for signs of resistance through regular scan assessments — usually every two to three months once your initial response is established — alongside your symptoms and blood tests. If a later scan shows the tumour growing again after a period of response or stability, your oncologist will investigate whether the cancer has developed a resistance mutation. There are subsequent treatment options designed for some resistance patterns in ALK-positive lung cancer, so progression on alectinib does not mean there are no further choices. Your team will discuss those options when and if they become relevant to you.

Yes. Alectinib is designed to cross the blood-brain barrier and is active against brain metastases as well as the primary tumour. The response timeline for brain metastases follows a similar pattern: the first CT scan at around eight to twelve weeks is the first objective measure of what is happening intracranially. If you have been diagnosed with brain metastases, tell your team promptly if you develop new headaches, vision changes, confusion, or any new neurological symptoms while on treatment — these need assessment sooner than your next scheduled scan, not at the next scheduled appointment.